APA (7th ed.) Citation

EF, S., MG, A., PS, U., MA, B., JA, N., DMO, H., . . . JN, B. (2022). Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: A first-in-patient, single-centre, single-arm, phase 1b trial. The Lancet. Oncology, 23(11), 1409. https://doi.org/10.1016/S1470-2045(22)00599-X

Chicago Style (17th ed.) Citation

EF, Spinazzi, et al. "Chronic Convection-enhanced Delivery of Topotecan for Patients with Recurrent Glioblastoma: A First-in-patient, Single-centre, Single-arm, Phase 1b Trial." The Lancet. Oncology 23, no. 11 (2022): 1409. https://doi.org/10.1016/S1470-2045(22)00599-X.

MLA (9th ed.) Citation

EF, Spinazzi, et al. "Chronic Convection-enhanced Delivery of Topotecan for Patients with Recurrent Glioblastoma: A First-in-patient, Single-centre, Single-arm, Phase 1b Trial." The Lancet. Oncology, vol. 23, no. 11, 2022, p. 1409, https://doi.org/10.1016/S1470-2045(22)00599-X.